Affymetrix, Inc. (NASDAQ:AFFX)
Engaged in the development, manufacture, sale and service of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets and create tools that advances the understanding of the molecular basis of life.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
this is going to 5$!
Recs
valuation, great potential
Recs
Deeply oversold and about to return to profitability so the stock should get above $6 in the next 3-12 months.
Recs
Insider buys. Growth sector.
Cash flows do not show the grim picture than accounting does.
Recs
strong buy
Recs
Knocked down quite badly today, but genetic testing is ramping up. As it becomes more common for companies to turn to this, AFFX will continue to grow.
Recs
great tech signs
Recs
nih grant
Recs
I'm counting on AFFX to innovate in the field of Genetic mapping, and bring their prices down to the same level or at least a more fitting level for their products. Plus, with the other Genetic Mapping companies in the game, I think they will all benefit in the next five years or so.
Recs
semiconductor sector starting to turn up.
Recs
can't get any lower
Recs
An out-of-favor provider of research tools and systems for genetic analysis that is poised to regain investor favor due to the need for innovation in biotech and pharma industry.
Recs
the stock has been beaten up and the chart is positive
Recs
Rule Breaker, Insiders, Sector bet
Recs
potential to do well in future
Recs
Cheap here...bounce over 20 likely in the next 12 months.
Recs
Insider Trading
Recs
their genotyping platform will be adapted more widely for personalized medicine tests to determine likely efficacy of drugs, and before that, used to establish those markers in R&D
Recs
April 30, 2008 5:30 PM EDT
Affymetrix Inc. (Nasdaq: AFFX) Chairman/Founder, Stephen P.A. Fodor, disclosed a purchase of 10,000 shares on 4/29 at $11.39, bringing his stake to 157,897 shares.
Shares of AFFX sunk 33% on 4/15 after the company lowered guidance.
Recs
Come on now. I understand that their earnings have been disappointing, but the bottom line is that this company is one of a few at the absolute cutting edge of modern-day genetics research. ILMN, perhaps its greatest competition, is seeing its stock price skyrocket, while AFFX continues to drop lower and lower.
This is one guy who thinks that this is about as low as she blows.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 54 : 1 2 3 Next »